# Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

> **NCT00698711** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** MUC-2-KLH

## Key facts

- **NCT ID:** NCT00698711
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2012-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698711, "Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00698711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*